Scientists Discover the Metabolic Enzyme That Turns Inflammation Into Muscle Wasting

Chronic obstructive pulmonary disease has long been known as a lung condition, but some of its most devastating consequences unfold far from the airways. Roughly a third of COPD patients also develop sarcopenia, the progressive loss of skeletal muscle mass, strength, and function, which robs them of mobility, worsens their quality of life, and increases their risk of death. For years, clinicians have observed that patients with this muscle-wasting complication carry elevated levels of the inflammatory cytokine tumor necrosis factor-alpha, or TNF-α, in their blood and within their muscles themselves. What they have lacked is a complete molecular explanation of how this inflammatory signal actually destroys muscle cells. A new study published in Aging Cell now traces the entire destructive pathway, from circulating inflammation to mitochondrial meltdown inside muscle progenitor cells, and identifies a single metabolic enzyme as the critical switch that turns chronic inflammation into muscle atrophy.

The research team, led by investigators at Fujian Medical University, began with a straightforward clinical observation. Analyzing serum samples from three groups of ten participants each—healthy controls, COPD patients without sarcopenia, and COPD patients with sarcopenia—they found that TNF-α stood out as one of the most significantly upregulated cytokines in the sarcopenic group. To model the disease in animals, the researchers exposed mice to cigarette smoke for 24 weeks and added two weeks of hindlimb unloading at the end, a two-hit design that reproduces both the chronic inflammatory burden of COPD and the physical deconditioning that advanced patients experience when breathlessness forces them into inactivity. These Se-Copd mice showed clear pulmonary inflammation, shrunken muscle fibers with a leftward shift in fiber size distribution, and dramatically elevated TNF-α both in serum and in gastrocnemius muscle tissue, confirming that the model faithfully captured the human phenotype.

With the clinical and animal foundations in place, the team turned to high-throughput RNA sequencing to discover what TNF-α actually does inside muscle cells. They treated C2C12 mouse myoblasts with the cytokine and profiled the resulting changes in gene expression. Principal component analysis cleanly separated treated from untreated cells, and pathway enrichment analysis delivered a striking result: the p53 signaling pathway, famous as the genome’s guardian and a central hub of cellular stress responses, was strongly activated among the differentially expressed genes. Both KEGG enrichment and gene set enrichment analysis confirmed the pattern. Among the genes responding to TNF-α, one stood out for its peculiar biochemistry: Prodh2, a mitochondrial enzyme that degrades hydroxyproline and, in doing so, directly generates mitochondrial reactive oxygen species.

Prodh2 had never before been implicated in skeletal muscle disease, making it a genuinely unexplored territory. The enzyme occupies a unique intersection of metabolism, oxidative stress, and signal transduction. Its catalytic reaction is an established source of mitochondrial superoxide, and the Prodh2 gene is a known transcriptional target of p53, the very pathway that TNF-α had just been shown to activate. The researchers confirmed that TNF-α treatment raised Prodh2 mRNA and protein levels in myoblasts in a dose-dependent fashion, with cellular damage rising in parallel as concentrations climbed from 5 to 20 nanograms per milliliter. The question then became whether Prodh2 was merely a bystander or the actual engine of destruction.

The answer came from a series of knockdown experiments that proved decisively that Prodh2 is necessary for nearly everything TNF-α does to muscle cells. When the researchers silenced Prodh2 with siRNA and then exposed the cells to the cytokine, the catastrophic cascade simply failed to launch. Mitochondrial ROS production, measured with MitoSox Red fluorescence, was blunted. The collapse of mitochondrial membrane potential, tracked by the JC-1 dye that shifts from red aggregates to green monomers as mitochondria fail, was prevented. The phosphorylation of the signaling molecules STING, IRF3, and p53 was abrogated. Cytoplasmic release of mitochondrial DNA, a hallmark of mitochondrial damage, was reversed. Cytotoxicity measured by lactate dehydrogenase release, apoptosis detected by TUNEL staining and cleaved caspase-3, and the suppression of proliferation measured by EdU incorporation were all rescued. Even the upregulation of the atrophy genes Atrogin-1 and MuRF1 vanished, and myotubes that would otherwise have shortened dramatically under TNF-α treatment retained their normal length.

To map the complete signaling chain, the team deployed a pharmacological toolkit. The p53 inhibitor Pifithrin-α completely blocked TNF-α’s ability to induce Prodh2 transcription, establishing that the cytokine upregulates the enzyme through p53-dependent transcription. Scavenging mitochondrial ROS with MitoTEMPO rescued cells from mitochondrial stress, proliferation arrest, apoptosis, and myotube atrophy, confirming that reactive oxygen species are the proximate mediators of the damage. Most remarkably, when the researchers overexpressed Prodh2 in cells whose p53 had been pharmacologically inhibited, the phosphorylation of STING and IRF3 returned, causally linking this single metabolic enzyme to the innate immune machinery. The pathway, in essence, runs in a straight line: TNF-α activates p53, p53 drives Prodh2 expression, Prodh2 floods mitochondria with ROS, damaged mitochondria release their DNA into the cytoplasm, and that mislocalized DNA triggers the cGAS/STING innate immune pathway.

This final step carries particular significance for the biology of aging. Mitochondrial DNA, being of prokaryotic origin, is recognized by the cytosolic DNA sensor cGAS as a danger signal when it escapes its organelle, provoking a type I interferon response and what researchers call sterile inflammation. Aberrant activation of this mtDNA-cGAS/STING axis has been implicated in renal fibrosis, atherosclerosis, cerebral ischemia-reperfusion injury, and, critically, in the chronic low-grade inflammation of aging known as inflammaging. Recent work has shown STING activation in muscle wasting associated with cirrhosis and COPD-related muscle senescence, but the upstream trigger inside muscle cells had remained mysterious. By identifying Prodh2-mediated ROS production as the initiator of mtDNA release, the study provides the first complete molecular answer to how metabolic dysregulation ignites innate immunity to drive sarcopenia.

The findings also cast p53 in an unexpected and darker role. Best known as a tumor suppressor, p53 has increasingly been recognized as a context-dependent driver of pathology in noncancerous diseases, promoting senescence and tissue dysfunction in neurodegeneration, skin aging, and ischemia-reperfusion injury when activated by chronic rather than acute stress. The study’s authors note that while earlier work in cancer cell lines found Prodh2 to be at best a weak p53 target under acute genotoxic stress, the robust induction they observed in myoblasts reflects a fundamentally different biological context: chronic inflammatory signaling through TNF-α, likely engaging distinct transcriptional co-factors or epigenetic states that render the Prodh2 promoter highly responsive in muscle progenitor cells.

Crucially, the team then asked whether blocking Prodh2 could treat the disease in living animals. Using adeno-associated viruses carrying shRNA injected directly into the gastrocnemius muscles of Se-Copd mice, they achieved targeted knockdown of the enzyme over a 12-week intervention period. The results were striking: treated mice recovered significant grip strength, their muscle fiber cross-sectional areas increased, atrophy markers Atrogin-1 and MuRF1 declined, and phosphorylation of p53, IRF3, and STING in muscle tissue was suppressed. Immunohistochemistry revealed that Prodh2 was diffusely overexpressed throughout the cytoplasm of mature contractile myofibers in the diseased animals, indicating that the pathway operates universally in muscle tissue under chronic inflammatory stress. Importantly, knocking down Prodh2 did not lower the animals’ serum TNF-α levels, demonstrating that the intervention works downstream of inflammation, at the point where inflammatory signals are translated into mitochondrial catastrophe.

The authors acknowledge limitations, including the lack of cell-type specificity in the AAV vector and the absence of histological data from other muscles such as the diaphragm, and they plan cell-specific Cre-LoxP studies to dissect the contributions of progenitors versus mature fibers. Nevertheless, the study delivers a complete mechanistic arc from clinic to molecule to therapy. It establishes a metabolic-immune crosstalk framework for sarcopenia in which a chronic inflammatory cytokine, acting through the ancient stress hub p53, repurposes a ordinary mitochondrial enzyme into an engine of self-destruction. In doing so, it positions Prodh2 as a druggable upstream node, offering hope that future interventions could protect the muscles of millions of COPD patients even while the inflammation itself continues to smolder in their lungs.

Subject of Research: The role of Prodh2-mediated mitochondrial stress in TNF-α-induced myoblast dysfunction and sarcopenia in COPD

Article Title: Prodh2‐Mediated Mitochondrial Stress Drives TNF‐α‐Induced Myoblast Dysfunction and Sarcopenia in COPD

Article References: Chen, G., Shangguan, Z., Gong, J., Cheng, D., Chen, P., Li, J., & Lin, Q. (2026). Prodh2‐Mediated Mitochondrial Stress Drives TNF ‐α‐Induced Myoblast Dysfunction and Sarcopenia in COPD. Aging Cell, 25(10), Article e70739. https://doi.org/10.1111/acel.70739

Image Credits: AI Generated

DOI: 10.1111/acel.70739

Keywords: COPD, sarcopenia, TNF-alpha, Prodh2, mitochondrial ROS, p53, STING, mitochondrial DNA, muscle atrophy, inflammation, myoblasts, Aging Cell